Biopolymer marker indicative of disease state having a molecular weight of 2753 daltons

Abstract

The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of said at least one disease state relative to recognition of the presence and/or the absence of said biopolymer.

1 . A method for screening for efficacy of disease process modulating agents for insulin resistance comprising: 
 (a) providing a sample of bodily fluid containing a biopolymer marker consisting of SEQ ID NO:1;    (b) adding a quantity of said agent sufficient to interact with said biopolymer marker consisting of SEQ ID NO:1; and    (c) determining the presence of an interaction between said agent and said biopolymer marker consisting of SEQ ID NO:1;    wherein said interaction is determinative of efficacy of said disease process modulating agent.    
     
     
         2 . A method for diagnosing insulin resistance comprising: 
 (a) providing a sample; and    (b) determining the presence of a biopolymer marker consisting of SEQ ID NO:1 in said sample;    wherein the presence of said biopolymer marker consisting of SEQ ID NO:1 is diagnostic for insulin resistance.    
     
     
         3 . The method of  claim 2 , wherein said sample is an unfractionated body fluid or a tissue sample.  
     
     
         4 . The method of  claim 2 , wherein said sample is selected from the group consisting of blood, blood products, urine, saliva, cerebrospinal fluid, and lymph.  
     
     
         5 . The method of  claim 2 , wherein said sample is from a human.